08
Jan
The Promise of ACNU A New Era in Self-Care and Market Innovation - Lachman Blog image

The Promise of ACNU: A New Era in Self-Care and Market Innovation

The pharmaceutical industry is entering a transformative era with the Food and Drug Administration’s (FDA) newly established pathway for nonprescription drug products with an Additional Condition for Nonprescription Use (ACNU), with the final rule announced in a December 2024 Federal Register Notice (here). This new rule aims to broaden consumer access to safe and effective […]

Read More
06
Jan
I make a list at the start of each day

Logbook Review: Too Simple To Automate?

The logbook is the original audit trail mechanism as predicated in Eudralex, Volume 4, Chapter 4, Section 4.31.  Is it too simple to automate or are we addicted to the simplicity of using them?  Regardless, the industry struggles to automate the review of one of the simplest controls.  In 2024, there were twenty-nine inspectional FDA 483s due to the […]

Read More
03
Jan
The Tirzepatide Chapter Three Rears Its Head

The Tirzepatide Chapter Three Rears Its Head – What Happens Now?

According to Fraiser Kansteiner’s article published on January 2, 2025 in Fierce Pharma (here), “Lilly on Wednesday filed a motion to intervene in a lawsuit brought by compounding industry group the Outsourcing Facilities Association (OFA) and compounder FarmaKeio Custom Compounding in U.S. District Court in Fort Worth, Texas.” As so the saga goes on. Lilly is […]

Read More
23
Dec
HolidayPost_2024_BlogImage

Holiday Greetings from Lachman Consultants

Just to add a little bit of folly, we have a short holiday poem for you to ponder! Due to the current uncertainty in the industry and the future leadership and priorities of the FDA, I’ve taken a somber tone in this season’s message. Maybe next year we can add some humor back into the […]

Read More
26
Nov
Warning message

FDA Updates Warning for All NSAIDs; Other Drugs to Come?

For those of you who follow the daily approvals page (here), on November 21, 2024, there was a flurry of supplemental labeling approvals listed for drug products that contain non-steroidal anti-inflammatory drugs (NSAIDs), from aspirin to Zipsor (diclofenac potassium).  In today’s CDER Drug Safety-related Labeling Changes (SrLC), the new, revised warning that must be included was […]

Read More
26
Nov
wooden cubes with the word Price on money pile of coins, business concept

Compounding, Unapproved Drugs, and Pricing – Nothing New Here But Still a Conundrum

Having been around the block more than a few times, the position of the FDA regarding pricing is clear.  The Agency is not supposed to take pricing considerations into drug approval or enforcement decisions.  However, there is controversy swirling around the FDA’s recent decision on the drug shortage for GPL-1 obesity medications and the practice […]

Read More
25
Nov
New FDA Commissioner Coming Soon - Lachman Blog

New FDA Commissioner Coming Soon to a Theater Near You

President-elect Donald Trump has selected Dr. Martin Makary to lead the Food and Drug Administration. Makary is a surgeon from Johns Hopkins who has been fairly outspoken regarding the Agency that oversees our drug and food supply. He appears to be critical of some of the Agency’s decision-making processes and it looks like he will insert […]

Read More
01
Nov
Blog Brief on Several FDA Actions and Topics of Interest - Lachman Blog Image 2

Brief on Several FDA Actions and Topics of Interest

Baxter Recovery and FDA Actions The FDA announced additional actions “to increase access to and supply of IV and peritoneal dialysis (PD) solutions following Hurricane Helene-related damage to Baxter International Inc.’s North Cove facility in Marion, North Carolina.”  The FDA performed assessments to enable import of IV solutions and PD solutions from seven different Baxter […]

Read More
1 2 139